Earnings ·
Corcept reports Q3 revenue of $340.5M and diluted EPS of $1.01, up 64% year-over-year
CORTCorcept Therapeutics Inc
Corcept Therapeutics reported third-quarter revenue of $340.5 million, a 64 percent increase from the prior year period, driven by strong uptake of its new oncology drug Lifyorli and growth in its endocrinology franchise. Net income rose to $126.8 million, or $1.01 per diluted share, compared to $19.7 million, or $0.16 per share, in the same quarter last year. The company reiterated its full-year 2026 revenue guidance of $1.1 billion to $1.2 billion and reported cash and investments of $662.3 million at quarter-end. Corcept Therapeutics is a commercial-stage biopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating cortisol effects.